6th Annual Pharma Packaging and Labeling USA 201426-27 February 2014, Philadelphia, USA
The 6th year of a truly successful and respected Pharma Packaging and Labeling event is rolling back into town with this year expected to be bigger than ever.
With key legislation on the horizon in California and the counterfeiting market now worth millions of dollars as well as sustainability and green packaging in demand, the need for this event is heightened.
We aim to bring you more compelling speakers talking about the subjects that matter to you. Following extensive research into the market we have been able identify key themes to discuss, issues to debate and people you want to meet all under one roof.
This outstanding event will provide a fantastic opportunity for exhibitors to promote their products and services to senior level decision makers from the region. Exhibition spaces are filling up due to the success of last year’s event as well as the global reputation of this world-renowned series.
Pharma Packaging and Labeling 2014 aims to target specific areas of the market in an interesting and insightful manner.
Rondo Pak would like to welcome all attendees of Pharma Packaging and Labeling to their drink reception taking place at the end of day one, on the 26th of February.
Swiss pharmaceutical firm Novartis has entered into an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance), to provide drug candidate compounds to fight tuberculosis (TB).
US-based pharmaceutical company Pfizer has submitted a new drug application (NDA) for palbociclib to the US Food and Drug Administration (FDA).
The All Wales Medicines Strategy Group (AWMSG) has recommended Bayer Healthcare’s Sativex Oromucosal Spray for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS).
Switzerland-based Roche has received approval from the US Food and Drug Administration (FDA) for its Avastin (bevacizumab), in combination with paclitaxel and cisplatin or paclitaxel and topotecan, to treat women with persistent, recurrent or metasta…
Biotechnology firm Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (RMS).